MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives $37.50 Average Target Price from Brokerages

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) have been assigned an average rating of “Hold” from the six analysts that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $37.50.

INKT has been the topic of a number of recent research reports. B. Riley upgraded MiNK Therapeutics to a “strong-buy” rating in a research report on Friday, July 18th. Zacks Research downgraded MiNK Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, August 18th. HC Wainwright upgraded MiNK Therapeutics from a “neutral” rating to a “buy” rating and set a $35.00 price target on the stock in a report on Friday, August 15th. Wall Street Zen downgraded MiNK Therapeutics to a “strong sell” rating in a report on Saturday, August 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of MiNK Therapeutics in a report on Wednesday, October 8th.

MiNK Therapeutics Price Performance

Shares of INKT stock opened at $14.15 on Friday. MiNK Therapeutics has a 1 year low of $4.56 and a 1 year high of $76.00. The stock’s 50 day simple moving average is $14.55 and its two-hundred day simple moving average is $11.85. The company has a market cap of $64.00 million, a PE ratio of -4.91 and a beta of 0.33.

MiNK Therapeutics (NASDAQ:INKT) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.51). Equities research analysts expect that MiNK Therapeutics will post -2.75 EPS for the current year.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.